Clinicians and nurses who treat patients with hemophilia with a gene therapy identified important factors and considerations needed in a potential shared decision making tool.
The article was originally published on CGTLive®.
A new paper published in Haemophilia has outlined the need for a shared decision making (SMD) tool for clinicians treating patients with gene therapy for hemophilia, and has proposed a tool to be refined and evaluated in clinical practice and real-world experiences.
“A clinician-oriented SDM tool may prepare clinicians to talk about gene therapy with persons with hemophilia and provide a systematic approach to the discussion,” study authors Jacqueline Limjoco, RN, and Courtney D. Thornburg, MD, both from Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital San Diego, wrote in the paper. “This study was designed to inform the development of a clinician SDM tool by understanding clinician experience with SDM and key gene therapy attributes to include in the tool.
The paper focused on decision making specifically for patients with hemophilia A being treated with valoctocogene roxaparvovec (val-rox; BioMarin), approved under the name Roctavian. Limjoco and Thornburg surveyed 10 clinicians and 2 nurses from the Hemophilia and Thrombosis Treatment Center that had 1 to 27 years of experience caring for patients with hemophilia.
The participants had no (n = 1), slight (n = 3), moderate (n = 5) and high (n = 1) confidence in having a clinical discussion about gene therapy and all agreed that an SDM tool would be useful for clinical practice. The participants gave feedback on language and presentation, content, and implementation of a potential tool, which should provide unbiased information and have companion tools with patient-centric language.
Regarding language and presentation, participants stressed the importance of specified definitions of terms for different types of bleeds or adverse events, which can be further simplified for patients. In terms of actual content of the tool, the participants identified the need for guidance concerning the process of gene therapy, including post-infusion follow-up, the safety, including need for immune suppression, the efficacy, including durability of response, as well as psychosocial impact, impact on family planning and alcohol consumption, and other factors including insurance coverage and other treatment options.
The participants thought that the tool should be unbiased and able to be updated. Another consideration that remains to be refined is whether the SDM tool should be split into 2 parts between provider and patient or combined into one.
“Data from this study demonstrates the need for provider education to increase confidence in discussing [gene therapy] and answering questions about safety and efficacy. This is like prior findings from provider surveys,” Limjoco and Thornburg wrote. “The tool includes resources for gene therapy education available through the National Hemophilia Foundation, the International Society of Thrombosis and Hemostasis, the World Federation of Hemophilia, etc. Participants are familiar with SDM but did not identify any specific tools to guide discussion of gene therapy. With the first approvals of hemophilia gene therapy, these tools are urgently needed.”
Reference
Limjoco J, Thornburg CD. Development of a haemophilia A gene therapy shared decision-making tool for clinicians. Haemophilia. 2023; 00-00. doi:10.1111/hae.14822
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
2 Commerce Drive
Cranbury, NJ 08512